Asset profile
SY-004
Small molecule
Evidence outlook · lead readout
NCT04217291 · Type 2 Diabetes Mellitus
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT04217291: The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 200 participants, but its primary endpoint was the surrogate measure of change in HbA1c rather than a hard clinical outcome. Because the registry does not report whether the primary comparison was favorable or statistically significant, the evidence is limited to a moderate grade.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.